You are here

A piece of news

Final stretch of CRAASH Barcelona with three days of training and speakers

This November was Barcelona Week, three days of speakers and training to help the six projects chosen for this year’s CRAASH Barcelona program continue validating their medical device and digital health innovations.

AddToAny buttons: 

The sessions covered several topics including how the digital ecosystem works, building relationships between startups and pharma companies, the steps to follow to get public funding, and investment and crowdequity processes.



On this final point, Capital Cell CEO Daniel Oliver explained how to raise funding in a competitive sector like healthcare.  “The biggest mistake people make in looking for funding is trying to get it from the wrong source,” he highlighted. Plus, Oliver noted the importance of the team in creating a new startup: “Observing the group can give you a good indication of whether the other elements work properly.”

Additionally, Laura Sampietro, deputy director of Innovation and head of Health Technology Assessment at Hospital Clinic, spoke about the process of validating a new medical technology: “Technological innovations have to be shown to improve the healthcare system and proven effective.” She also referenced Europe’s great capacity to produce and develop innovations in the healthcare arena and how they can be funded. “New technology is a huge challenge to how healthcare systems are funded.”

Other speakers included Eva Rosell, Strategic Projects director at Tech Barcelona; Gemma Estrada, director of Digital Health and Technology at Ferrer; Katharine D’Amico, Communication Strategy and Pitch Deck Management at ESADE Business School; Xavier Berthet, CEO of x+b.i; Daniel Oliver, CEO of Capital Cell; Laura Sampietro, deputy director of Innovation and head of Health Technology Assessment at Hospital Clinic; Jana Arimany and Ariadna Balmes, patients taking part in the Able Human Motion project; Luis García, Senior Digital Health Business Development manager at DKV; Marc Ramis, CEO of Rejuversen AG; and Tito Español, Product manager at Antai Venture Builder.

Related content: